Transverse aortic constriction induces gut barrier alterations, microbiota remodeling and systemic inflammation.
Animals
Aortic Valve Stenosis
/ complications
Biomarkers
Disease Models, Animal
Disease Susceptibility
Dysbiosis
Echocardiography
Feces
/ microbiology
Gastrointestinal Microbiome
Heart Failure
/ diagnosis
Heart Function Tests
Inflammation
/ etiology
Intestinal Mucosa
/ metabolism
Metagenome
Metagenomics
/ methods
Mice
Permeability
Ventricular Remodeling
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
30
07
2020
accepted:
15
03
2021
entrez:
2
4
2021
pubmed:
3
4
2021
medline:
23
11
2021
Statut:
epublish
Résumé
Accumulating evidence suggests that modifications of gut function and microbiota composition might play a pivotal role in the pathophysiology of several cardiovascular diseases, including heart failure (HF). In this study we systematically analysed gut microbiota composition, intestinal barrier integrity, intestinal and serum cytokines and serum endotoxin levels in C57BL/6 mice undergoing pressure overload by transverse aortic constriction (TAC) for 1 and 4 weeks. Compared to sham-operated animals, TAC induced prompt and strong weakening of intestinal barrier integrity, long-lasting decrease of colon anti-inflammatory cytokine levels, significant increases of serum levels of bacterial lipopolysaccharide and proinflammatory cytokines. TAC also exerted effects on microbiota composition, inducing significant differences in bacterial genera inside Actinobacteria, Firmicutes, Proteobacteria and TM7 phyla as shown by 16S rDNA sequencing of fecal samples from TAC or sham mice. These results suggest that gut modifications represent an important element to be considered in the development and progression of cardiac dysfunction in response to TAC and support this animal model as a valuable tool to establish the role and mechanisms of gut-heart crosstalk in HF. Evidence arising in this field might identify new treatment options targeting gut integrity and microbiota components to face adverse cardiac events.
Identifiants
pubmed: 33795775
doi: 10.1038/s41598-021-86651-y
pii: 10.1038/s41598-021-86651-y
pmc: PMC8016915
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7404Références
Nature. 2006 Dec 21;444(7122):1009-10
pubmed: 17183300
Environ Microbiol. 2017 Mar;19(3):835-841
pubmed: 28028921
J Card Fail. 2016 Nov;22(11):891-900
pubmed: 27317844
Curr Opin Cardiol. 2007 Sep;22(5):443-9
pubmed: 17762546
J Am Coll Cardiol. 2007 Oct 16;50(16):1561-9
pubmed: 17936155
Nature. 2012 Oct 4;490(7418):55-60
pubmed: 23023125
Open Heart. 2019 Apr 23;6(1):e000993
pubmed: 31168383
Sci Rep. 2019 Mar 18;9(1):4832
pubmed: 30886232
PLoS One. 2016 May 02;11(5):e0154076
pubmed: 27136357
Nat Biotechnol. 2013 Sep;31(9):814-21
pubmed: 23975157
Circ Heart Fail. 2016 Jan;9(1):e002314
pubmed: 26699388
J Am Coll Cardiol. 2018 Mar 13;71(10):1184-1186
pubmed: 29519360
World J Gastroenterol. 2011 Mar 28;17(12):1519-28
pubmed: 21472114
Sci Rep. 2017 Mar 28;7:45356
pubmed: 28349974
Cardiovasc Res. 2015 Sep 1;107(4):431-41
pubmed: 26101262
Int Heart J. 2019;60(5):1176-1183
pubmed: 31564708
J Am Coll Cardiol. 2014 Sep 16;64(11):1092-102
pubmed: 25212642
Eur J Heart Fail. 2004 Jun;6(4):403-7
pubmed: 15182764
Nat Rev Cardiol. 2019 Mar;16(3):137-154
pubmed: 30410105
Front Physiol. 2018 May 28;9:558
pubmed: 29892230
World J Gastroenterol. 2015 Aug 7;21(29):8787-803
pubmed: 26269668
Biomed Pharmacother. 2019 Dec;120:109482
pubmed: 31568990
Trends Cardiovasc Med. 2019 Apr;29(3):141-147
pubmed: 30126689
Hypertension. 2015 Jun;65(6):1331-40
pubmed: 25870193
BMC Microbiol. 2016 May 25;16:90
pubmed: 27220822
Gastroenterol Res Pract. 2016;2016:4953120
pubmed: 26880890
J Med Microbiol. 2008 Dec;57(Pt 12):1569-1576
pubmed: 19018031
JACC Heart Fail. 2016 Mar;4(3):220-7
pubmed: 26682791
ESC Heart Fail. 2017 Aug;4(3):282-290
pubmed: 28772054
BMC Bioinformatics. 2015 Oct 08;16:324
pubmed: 26450747
Sci Rep. 2018 Jan 12;8(1):635
pubmed: 29330424
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
Lab Anim. 2019 Oct;53(5):447-458
pubmed: 30522404
Biochem Pharmacol. 1993 Jun 22;45(12):2435-9
pubmed: 8328981
Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):821-834
pubmed: 28650209
Oncogene. 2020 Jun;39(26):4925-4943
pubmed: 32514151
Circulation. 2006 Feb 21;113(7):929-37
pubmed: 16490835
Circ Res. 2017 Mar 31;120(7):1183-1196
pubmed: 28360349
Front Physiol. 2014 Mar 03;5:12
pubmed: 24624088
J Am Heart Assoc. 2020 May 18;9(10):e016223
pubmed: 32390485
JAMA. 1993 Sep 8;270(10):1203-10
pubmed: 8355382
J Clin Invest. 2006 Jun;116(6):1547-60
pubmed: 16741575
Card Fail Rev. 2019 May 24;5(2):119-122
pubmed: 31179023
Gut. 2009 Aug;58(8):1091-103
pubmed: 19240062
Eur Heart J. 2017 Oct 14;38(39):2948-2956
pubmed: 29020409
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Microbiome. 2018 Apr 3;6(1):66
pubmed: 29615110
Sci Rep. 2018 Oct 10;8(1):15072
pubmed: 30305667
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
PLoS One. 2017 Mar 22;12(3):e0174099
pubmed: 28328981